These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 32081238)

  • 21. Increased mortality with paclitaxel-eluting stents is driven by lesion length.
    Mathlouthi A; Yei KS; Naazie I; Bertges DJ; Malas MB
    J Vasc Surg; 2021 Feb; 73(2):548-553.e2. PubMed ID: 32615286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent.
    Golzar J; Soga Y; Babaev A; Iida O; Kawasaki D; Bachinsky W; Park J; Prem JT; Vermassen F; Diaz-Cartelle J; Müller-Hülsbeck S; Gray WA
    J Endovasc Ther; 2020 Apr; 27(2):296-303. PubMed ID: 31989856
    [No Abstract]   [Full Text] [Related]  

  • 23. 1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.
    Bisdas T; Beropoulis E; Argyriou A; Torsello G; Stavroulakis K
    JACC Cardiovasc Interv; 2018 May; 11(10):957-966. PubMed ID: 29798772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries.
    Phillips JA; Falls A; Kolluri R; Whipp A; Collins C; Mohir-Sadaai S; Reid B; Patil N; Alston M; Troyan M; Ansel GM
    J Endovasc Ther; 2018 Jun; 25(3):295-301. PubMed ID: 29544372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
    Fujihara M; Utsunomiya M; Higashimori A; Yokoi Y; Nakamura M
    Heart Vessels; 2016 Feb; 31(2):152-7. PubMed ID: 25351136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup.
    Bosiers M; Peeters P; Tessarek J; Deloose K; Strickler S;
    J Cardiovasc Surg (Torino); 2013 Feb; 54(1):115-22. PubMed ID: 23296421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
    Sugimoto M; Komori K; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
    J Endovasc Ther; 2021 Apr; 28(2):229-235. PubMed ID: 33084502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent.
    Müller-Hülsbeck S; Benko A; Soga Y; Fujihara M; Iida O; Babaev A; O'Connor D; Zeller T; Dulas DD; Diaz-Cartelle J; Gray WA
    Cardiovasc Intervent Radiol; 2021 Mar; 44(3):368-375. PubMed ID: 33225377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
    Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
    J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
    [No Abstract]   [Full Text] [Related]  

  • 31. Predictors of recurrence after paclitaxel drug-coated balloon use for treating femoropopliteal in-stent restenosis.
    Taha AG; Saleh MI; Ali H; Gamal WM
    Vascular; 2024 Aug; 32(4):834-841. PubMed ID: 36896828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZILVERPASS Study: ZILVER PTX Stent vs. Bypass Surgery in Femoropopliteal Lesions, 3 year results and economic analysis.
    Bosiers M; DE Donato G; Torsello G; Galvagni Silveira P; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Tessarek J; Giaquinta A; van den Eynde W; Verbist J; Wahl-Gravsen J; Bosiers MJ
    J Cardiovasc Surg (Torino); 2023 Aug; 64(4):413-421. PubMed ID: 37162238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
    Bosiers M; Callaert J; Keirse K; Hendriks JMH; Peeters P; Verbist J; Maene L; Beelen R; Deloose K
    J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall Healing after IMplantation of drug Eluting peripheral stent in Japanese patients with the Infra inguinal lesion: serial angioscopic observation).
    Tsukiyama Y; Shinke T; Ishihara T; Otake H; Terashita D; Kozuki A; Fukunaga M; Zen K; Horimatsu T; Fujii K; Shite J; Uematsu M; Takahara M; Iida O; Nanto S; Hirata KI
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1777-1784. PubMed ID: 31201589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of SFA lesion treatment with Zilver PTX in diabetics vs. non-diabetics: 2-year clinical and functional results.
    Oberto S; Cetta F; Trabattoni P; Zoli S; Tavano D; Rossi F; Clerici G; Airoldi F; Spirito R; Losa S
    J Cardiovasc Surg (Torino); 2017 Aug; 58(4):565-573. PubMed ID: 25791358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results.
    Bosiers MJ; De Donato G; Torsello G; Silveira PG; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Eckstein HH; Teβarek J; Giaquinta A; van den Eynde W; Verbist J; Callaert J; Deloose K; Bosiers M
    Cardiovasc Intervent Radiol; 2023 Oct; 46(10):1348-1358. PubMed ID: 37670198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
    Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
    J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Trial Comparing a Stent-Avoiding With a Stent-Preferred Strategy in Complex Femoropopliteal Lesions.
    Wittig T; Schmidt A; Fuß T; Thieme M; Maiwald L; Düsing S; Konert M; Fischer A; Scheinert D; Steiner S
    JACC Cardiovasc Interv; 2024 May; 17(9):1134-1144. PubMed ID: 38749594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.